• In late June 2026, Brown-Forman’s Class A (NYSE: BF.A) and Class B (NYSE: BF.B) shares were added to multiple Russell benchmarks, including the Russell 1000 Dynamic Index, Russell 2500 Index, and Russell 2500 Value Benchmark.
• This cluster of index inclusions can increase Brown-Forman’s visibility and trading activity, as index-tracking funds adjust portfolios to incorporate the stock.
• Next, we’ll examine how Brown-Forman’s multiple Russell index additions may influence its investment narrative and long-term positioning.

Find 45 companies with promising cash flow potential yet trading below their fair value.

Brown-Forman Investment Narrative Recap

To own Brown-Forman, you need to believe its portfolio of premium spirits can stay relevant despite softer demand, health-driven moderation, and rising competition. The recent Russell index additions may support trading liquidity and visibility, but they do not directly change the near term focus on stabilizing earnings after a weaker FY2026 or the key risk that long term spirits consumption in core developed markets could face structural pressure.

Among recent announcements, the April 2026 decision to end M&A talks with Pernod Ricard and “focus on strategic priorities and growth” stands out alongside these index changes. Together, they frame Brown-Forman as an independent, stand alone spirits business that is trying to improve execution, including U.S. distribution realignment and ongoing buybacks, while the main catalysts remain operational rather than index related.

Yet beneath the added index visibility, investors still need to weigh the possibility that changing drinking habits and rising health concerns could...

Brown-Forman's narrative projects $4.1 billion revenue and $811.1 million earnings by 2029. This requires 1.7% yearly revenue growth and about a $96.1 million earnings increase from $715.0 million today.

Uncover how Brown-Forman's forecasts yield a $28.02 fair value, a 8% upside to its current price.

Exploring Other Perspectives

Compared with the consensus view, the most bearish analysts were already assuming roughly flat revenue at about US$3.9 billion and only modest earnings growth to about US$728 million, which is a far more cautious take on Brown-Forman’s future than the more optimistic belief in premiumization and emerging market expansion.

Explore 6 other fair value estimates on Brown-Forman - why the stock might be worth as much as 49% more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Brown-Forman research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Brown-Forman research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Brown-Forman's overall financial health at a glance.

Seeking Other Investments?

Our top stock finds are flying under the radar-for now. Get in early:

• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.